Back to Journals » OncoTargets and Therapy » Volume 12

Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report

Authors Chen X, Zhang Y, Zhang N, Ge Y, Jia W

Received 25 May 2019

Accepted for publication 19 August 2019

Published 9 September 2019 Volume 2019:12 Pages 7355—7359

DOI https://doi.org/10.2147/OTT.S217123

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Rachel Predeepa

Peer reviewer comments 3

Editor who approved publication: Dr Takuya Aoki


Video abstract presented by Xin Chen.

Views: 98

Xin Chen1,2, Yazhou Zhang1,2, Nu Zhang1,2, Yongsheng Ge1,2, Weidong Jia1,2

1Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230001, People’s Republic of China; 2Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, Anhui Province 230001, People’s Republic of China

Correspondence: Weidong Jia
Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, No.17, Lu Jiang Road, Hefei, Anhui Province 230001, People’s Republic of China
Tel +86 551 6228 3740
Fax +86 551 6228 3740
Email jwd1968@sina.com

Abstract: Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor. The survival of advanced HCC is very poor. In this case study, we describe the treatment of a 69-year-old woman diagnosed with massive hepatocellular carcinoma, the use of lenvatinib in combination with nivolumab injection in the preoperative adjuvant treatment of advanced massive hepatocellular carcinoma, and the final taking extended right hepatectomy. Molecular targeted drugs and immunotherapy controlled patient’s condition to create time and conditions for surgery. After surgery, AFP was greatly reduced, no recurrence of the residual liver and no metastasis in the distance. This treatment is the gospel of patients with advanced liver cancer.

Keywords: HCC, lenvatinib, nivolumab injection, hepatectomy, combination therapy


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]